Identification of Factors Affecting Tacrolimus Trough Levels in Latin American Pediatric Liver Transplant Patients
暂无分享,去创建一个
M. D. de Dávila | A. Mangano | J. Woillard | P. Schaiquevich | N. Riva | O. Imventarza | M. Moragas | M. Dip | M. Distefano | P. Cáceres Guido | Andrea Bosaleh | N. Licciardone | E. Halac | Maximiliano Distefano
[1] J. Klawitter,et al. Assessment of tacrolimus intrapatient variability in stable adherent transplant recipients: Establishing baseline values , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[2] D. Mager,et al. Population Pharmacokinetics of Tacrolimus in Transplant Recipients: What Did We Learn About Sources of Interindividual Variabilities? , 2018, Journal of clinical pharmacology.
[3] M. Lafreniere-Roula,et al. A randomized clinical trial of age and genotype‐guided tacrolimus dosing after pediatric solid organ transplantation , 2018, Pediatric transplantation.
[4] Dan S. Borgnia,et al. Survival Time to Biopsy-Proven Acute Rejection and Tacrolimus Adverse Drug Reactions in Pediatric Liver Transplantation , 2018, Therapeutic drug monitoring.
[5] C. Ensor,et al. Increasing tacrolimus time‐in‐therapeutic range is associated with superior one‐year outcomes in lung transplant recipients , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[6] A. Åsberg,et al. Pharmacokinetic models to assist the prescriber in choosing the best tacrolimus dose , 2018, Pharmacological research.
[7] D. Hesselink,et al. A Population Pharmacokinetic Model to Predict the Individual Starting Dose of Tacrolimus Following Pediatric Renal Transplantation , 2017, Clinical Pharmacokinetics.
[8] P. Schaiquevich,et al. Pharmacoepidemiology of tacrolimus in pediatric liver transplantation , 2017, Pediatric transplantation.
[9] A. Amoroso,et al. Donor CYP3A5 genotype influences tacrolimus disposition on the first day after paediatric liver transplantation , 2017, British journal of clinical pharmacology.
[10] D. Sautereau,et al. Influence of Donor and Recipient CYP3A4, CYP3A5, and ABCB1 Genotypes on Clinical Outcomes and Nephrotoxicity in Liver Transplant Recipients , 2016, Transplantation.
[11] J. Otte. Pediatric liver transplantation: Personal perspectives on historical achievements and future challenges , 2016, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[12] L. Weber,et al. Therapeutic monitoring of immunosuppressive drugs in pediatric patients: special considerations , 2016, Expert review of clinical pharmacology.
[13] C. Staatz,et al. Assessing Predictive Performance of Published Population Pharmacokinetic Models of Intravenous Tobramycin in Pediatric Patients , 2016, Antimicrobial Agents and Chemotherapy.
[14] Julia M. Barbarino,et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing , 2015, Clinical pharmacology and therapeutics.
[15] Y. Zhang,et al. Population pharmacokinetic analysis of tacrolimus early after Chinese pediatric liver transplantation. , 2015, International journal of clinical pharmacology and therapeutics.
[16] Jian-jun Zhang,et al. Personalized Tacrolimus Dose Requirement by CYP3A5 but Not ABCB1 or ACE Genotyping in Both Recipient and Donor after Pediatric Liver Transplantation , 2014, PloS one.
[17] C. Staatz,et al. Effects of Combinational CYP3A5 6986A>G Polymorphism in Graft Liver and Native Intestine on the Pharmacokinetics of Tacrolimus in Liver Transplant Patients: A Meta-Analysis , 2014, Therapeutic drug monitoring.
[18] D. Bates,et al. Fitting Linear Mixed-Effects Models Using lme4 , 2014, 1406.5823.
[19] J. McElnay,et al. Population pharmacokinetic and pharmacogenetic analysis of tacrolimus in paediatric liver transplant patients , 2014, British journal of clinical pharmacology.
[20] P. Wallemacq,et al. Population Pharmacokinetic Analysis of Tacrolimus Early After Pediatric Liver Transplantation , 2013, Therapeutic drug monitoring.
[21] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[22] D. Hesselink,et al. The Role of Pharmacogenetics in the Disposition of and Response to Tacrolimus in Solid Organ Transplantation , 2014, Clinical Pharmacokinetics.
[23] Bodo Winter,et al. Linear models and linear mixed effects models in R with linguistic applications , 2013, ArXiv.
[24] C. Verstuyft,et al. Tacrolimus dose requirement in pediatric liver transplantation: influence of CYP3A5 gene polymorphism. , 2013, Pharmacogenomics.
[25] P. Marquet,et al. Lessons From Routine Dose Adjustment of Tacrolimus in Renal Transplant Patients Based on Global Exposure , 2013, Therapeutic drug monitoring.
[26] P. Wallemacq,et al. Population pharmacokinetic analysis of tacrolimus in the first year after pediatric liver transplantation , 2013, European Journal of Clinical Pharmacology.
[27] M. Karlsson,et al. Population Pharmacokinetics of Tacrolimus in Pediatric Liver Transplantation: Early Posttransplantation Clearance , 2011, Therapeutic drug monitoring.
[28] G. Koren,et al. The interactions of age, genetics, and disease severity on tacrolimus dosing requirements after pediatric kidney and liver transplantation , 2011, European Journal of Clinical Pharmacology.
[29] B. McCrindle,et al. Variability in tacrolimus blood levels increases the risk of late rejection and graft loss after solid organ transplantation in older children , 2010, Pediatric transplantation.
[30] C. Staatz,et al. Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part I , 2010, Clinical pharmacokinetics.
[31] D. Kelly,et al. Calcineurin inhibitor minimization in pediatric liver allograft recipients , 2009, Pediatric transplantation.
[32] V. Haufroid,et al. Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus Conference , 2009, Therapeutic drug monitoring.
[33] B. Charpentier,et al. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients. , 2008, Basic & clinical pharmacology & toxicology.
[34] S. Uemoto,et al. Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living‐donor liver transplant recipients , 2006, Clinical pharmacology and therapeutics.
[35] D. Kelly. Current issues in pediatric transplantation , 2006, Pediatric transplantation.
[36] M. Hebert,et al. EFFECT OF CYP3A5 POLYMORPHISM ON TACROLIMUS METABOLIC CLEARANCE IN VITRO , 2006, Drug Metabolism and Disposition.
[37] S. Masuda,et al. CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. , 2004, Pharmacogenetics.
[38] C. Staatz,et al. Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation , 2004, Clinical pharmacokinetics.
[39] C. Staatz,et al. Population pharmacokinetics of tacrolimus in adult kidney transplant recipients , 2002, Clinical pharmacology and therapeutics.
[40] M. Stoll,et al. Pediatric , 1997, Bone Marrow Transplantation.
[41] Ann Daly,et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression , 2001, Nature Genetics.
[42] C. Manzanares,et al. Covariate Effects on the Apparent Clearance of Tacrolimus in Paediatric Liver Transplant Patients Undergoing Conversion Therapy , 2001, Clinical Pharmacokinetics.
[43] S. Chan,et al. Population pharmacokinetics of tacrolimus in Asian paediatric liver transplant patients. , 2000, British journal of clinical pharmacology.
[44] M. Brunet,et al. Influence of posttransplant time on dose and concentration of tacrolimus in liver transplant patients , 1998, Transplant international : official journal of the European Society for Organ Transplantation.
[45] J. Hooff,et al. Effect of breakfast on the oral bioavailability of tacrolimus and changes in pharmacokinetics at different times posttransplant in renal transplant recipients. , 1998, Transplantation proceedings.
[46] S. Todo,et al. Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine. , 1991, Transplantation proceedings.